Clinico-pathological characteristics among South African women with breast cancer receiving anti-retroviral therapy for HIV.


Journal

Breast (Edinburgh, Scotland)
ISSN: 1532-3080
Titre abrégé: Breast
Pays: Netherlands
ID NLM: 9213011

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 08 11 2018
revised: 04 12 2018
accepted: 06 12 2018
pubmed: 15 12 2018
medline: 29 5 2019
entrez: 15 12 2018
Statut: ppublish

Résumé

Breast cancer is the most common cancer in women and a leading cause of cancer-related mortality worldwide. South Africa has the largest global burden of HIV infection and the largest anti-retroviral treatment (ART) program. This study aimed to analyse the association of HIV and ART use with breast cancer clinico-pathological characteristics. Study participants were females, newly diagnosed from May 2015 through September 2017 with invasive breast cancer at two academic Surgical Breast Units in Johannesburg, South Africa at the Charlotte Maxeke Johannesburg Academic Hospital and Chris Hani Baragwanath Academic Hospital. We compared HIV-positive and HIV negative patients' demographic and clinical-pathological characteristics at the time of breast cancer diagnosis. Of 1050 patients enrolled, 1016 (96.8%) had known HIV status, with 226 (22.2%) being HIV positive. HIV positive patients were younger (median (IQR) age 45 (40-52) years), than HIV-negative patients (median (IQR) age 57 (46-67)) (p < 0.001). HIV positive patients were more likely to be diagnosed with late stage breast cancer (p = 0.01). However, HIV positive patients receiving ART at the time of breast cancer diagnosis were less likely to present with metastatic disease than those not on ART (p = 0.05). HIV-positive patients present with breast cancer at a younger age and later stage disease than HIV-negative patients. Neither the duration of HIV infection nor ART use was associated with clinico-pathological characteristics of breast cancer.

Identifiants

pubmed: 30550925
pii: S0960-9776(18)30334-5
doi: 10.1016/j.breast.2018.12.005
pmc: PMC6369009
mid: NIHMS1516499
pii:
doi:

Substances chimiques

Anti-HIV Agents 0
Ki-67 Antigen 0
MKI67 protein, human 0
Receptors, Estrogen 0
Receptors, Progesterone 0
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

123-129

Subventions

Organisme : NCI NIH HHS
ID : P30 CA013696
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA192627
Pays : United States

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Références

Am J Epidemiol. 2007 May 15;165(10):1143-53
pubmed: 17344204
Med Oncol. 2012 Jun;29(2):446-7
pubmed: 21328085
J Natl Med Assoc. 2000 Jun;92(6):301-5
pubmed: 10918766
J Glob Oncol. 2018 Sep;4:1-11
pubmed: 30241185
Mod Pathol. 2005 Aug;18(8):1067-78
pubmed: 15920556
S Afr Med J. 2017 Jun 30;107(7):595-601
pubmed: 29025449
J Glob Oncol. 2018 Sep;4:1-9
pubmed: 30241147
Radiother Oncol. 2015 Aug;116(2):323-30
pubmed: 26183311
AIDS. 2018 Mar 27;32(6):773-782
pubmed: 29369158
Eur J Cancer. 2012 Dec;48(18):3335-41
pubmed: 22766516
Int J Cancer. 2018 Dec 1;143(11):2732-2740
pubmed: 29992553
J Int Assoc Physicians AIDS Care (Chic). 2011 Jan-Feb;10(1):30-4
pubmed: 21368012
J Acquir Immune Defic Syndr. 2009 Dec;52(5):611-22
pubmed: 19770804
Crit Rev Oncol Hematol. 2009 Oct;72(1):10-20
pubmed: 19070506
AIDS. 2014 Nov;28 Suppl 4:S453-9
pubmed: 25222641
Clin Breast Cancer. 2001 Oct;2(3):215-20; discussion 221
pubmed: 11899415
Int J Surg. 2016 Oct;34:109-115
pubmed: 27573692
J Glob Oncol. 2017 Apr;3(2):114-124
pubmed: 28706996
Ann Oncol. 2011 Aug;22(8):1736-47
pubmed: 21709140
PLoS One. 2018 Feb 2;13(2):e0192071
pubmed: 29394271
Arch Pathol Lab Med. 2014 May;138(5):595-601
pubmed: 24236805
Oncologist. 2015 Jul;20(7):780-8
pubmed: 26032138
BMC Health Serv Res. 2017 Jan 21;17(1):63
pubmed: 28109290
JAMA. 2015 Jan 13;313(2):165-73
pubmed: 25585328
Eur J Med Res. 2011 Mar 28;16(3):101-7
pubmed: 21486722
Int J Cancer. 2014 Nov 1;135(9):2173-82
pubmed: 24658866
Biomed Res Int. 2014;2014:628217
pubmed: 24783217
South Afr J HIV Med. 2017 Jul 15;18(1):776
pubmed: 29568644
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Breast Cancer Res Treat. 2013 Jul;140(1):177-86
pubmed: 23801159
SA J Radiol. 2018 Aug 30;22(2):1361
pubmed: 31754516

Auteurs

Boitumelo Phakathi (B)

Charlotte Maxeke Surgical Breast Unit, Charlotte Maxeke Johannesburg Academic Hospital, Jubilee Road, Johannesburg, 2196, South Africa; Department of Surgery, University of the Witwatersrand Faculty of Health Sciences, 7 York Road, Johannesburg, 2193, South Africa. Electronic address: boitumelo.phakathi@wits.ac.za.

Herbert Cubasch (H)

Batho Pele Breast Unit, Chris Hani Baragwanath Academic Hospital, 26 Chris Hani Road, Diepkloof, Soweto, 1860, South Africa; Non-Communicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, 31 Princess of Wales Building, Johannesburg, 2193, South Africa.

Sarah Nietz (S)

Charlotte Maxeke Surgical Breast Unit, Charlotte Maxeke Johannesburg Academic Hospital, Jubilee Road, Johannesburg, 2196, South Africa; Department of Surgery, University of the Witwatersrand Faculty of Health Sciences, 7 York Road, Johannesburg, 2193, South Africa.

Caroline Dickens (C)

Department of Medicine, University of Witwatersrand Faculty of Health Sciences, 7 York Road Johannesburg, South Africa.

Therese Dix-Peek (T)

Department of Medicine, University of Witwatersrand Faculty of Health Sciences, 7 York Road Johannesburg, South Africa.

Maureen Joffe (M)

Non-Communicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, 31 Princess of Wales Building, Johannesburg, 2193, South Africa; MRC Developmental Pathways to Health Research Unit, Department of Paediatrics, University of Witwatersrand Faculty of Health Sciences, 7 York Road, Johannesburg, South Africa.

Alfred I Neugut (AI)

Herbert Irving Comprehensive Cancer Centre, Vagelos College of Physicians and Surgeons, Columbia University, New York, USA.

Judith Jacobson (J)

Herbert Irving Comprehensive Cancer Centre, Vagelos College of Physicians and Surgeons, Columbia University, New York, USA; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, USA.

Raquel Duarte (R)

Department of Medicine, University of Witwatersrand Faculty of Health Sciences, 7 York Road Johannesburg, South Africa.

Paul Ruff (P)

Non-Communicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, 31 Princess of Wales Building, Johannesburg, 2193, South Africa; Department of Medicine, University of Witwatersrand Faculty of Health Sciences, 7 York Road Johannesburg, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH